Dita Gratzinger, MD, Pathology, Stanford, CA, Lucile Packard Children's Hospital Stanford

DitaGratzingerMDPhD

Pathology Stanford, CA

Hematopathology, Anatomic Pathology

Associate Professor, Pathology, Stanford University Medical Center

Dr. Gratzinger is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gratzinger's full profile

Already have an account?

Summary

  • I am an academic hematopathologist with a broad clinical practice including adult and pediatric bone marrow, blood, lymph node and flow cytometry. I am involved in training residents and fellows as part of my daily practice. I have significant translational research interests in the interaction of stroma and vasculature with hematopoietic malignancy, including myelodysplastic syndromes and lymphoma.

Education & Training

  • Stanford University
    Stanford UniversityFellowship, Hematopathology, 2006 - 2007
  • Stanford University
    Stanford UniversityFellowship, Surgical Pathology, 2005 - 2006
  • Stanford University
    Stanford UniversityResidency, Anatomic and Clinical Pathology, 2003 - 2006
  • Yale University School of Medicine
    Yale University School of MedicineClass of 2003

Certifications & Licensure

  • NV State Medical License
    NV State Medical License 2013 - 2021
  • CA State Medical License
    CA State Medical License 2004 - 2022
  • American Board of Pathology Pathology - Anatomic
  • American Board of Pathology Hematopathology

Publications & Presentations

PubMed

Press Mentions

  • Corrigendum to “KB004, a First in Class Monoclonal Antibody Targeting the Receptor Tyrosine Kinase EphA3, in Patients with Advanced Hematologic Malignancies: Results from a Phase 1 Study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
    Corrigendum to “KB004, a First in Class Monoclonal Antibody Targeting the Receptor Tyrosine Kinase EphA3, in Patients with Advanced Hematologic Malignancies: Results from a Phase 1 Study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]August 25th, 2017

Hospital Affiliations